Blog example


Nicky Veringmeier
Marketing
Your content goes here. Edit or remove this text inline or in the module Content settings.
You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
The multi-product facility is designed to support the late-stage clinical manufacturing and commercial manufacturing of vaccines and viral vector-based gene therapy and immune-oncology products.
Batavia’s highly intensified manufacturing technology, HIP-Vax®, which utilizes fixed-bed bioreactors, will be the main platform, but also products manufactured using traditional mammalian cell suspension technologies up to 1000L scale can readily be delivered. The facility is based on a modular design, with 6 production suites. On-site, state-of-the-art fill / finish capabilities ensure on-time delivery of drug product. Depending on virus / vector type the facility is expected to provide for several hundred million doses annually.
Related
Batavia Biosciences to manufacture Marburg vaccine for IAVI under $35.7M DTRA grant
Leiden, the Netherlands, Nov 12, 2019 – We are proud to announce that we have partnered with IAVI under an award they have received from the US Defense Threat Reduction Agency (DTRA) to develop a VSV-based vaccine against Marburg virus. (Link to IAVI press...
Batavia manufactures LASV vaccine candidate for IAVI who today announced the first vaccinations of their Lassa fever vaccine candidate
Batavia Biosciences would like to congratulate IAVI on their press release, as today they've announced volunteers in Monrovia, Liberia have been vaccinated with IAVI’s novel vaccine candidate against Lassa fever virus (LASV) in a Phase I clinical trial, named...
Univercells and consortium partners Batavia Biosciences and Natrix Separations Received $12 Million Grant by Bill & Melinda Gates Foundation to Radically Reduce Vaccine Costs for Developing Countries
Brussels, Belgium, December 15, 2016 – Univercells announced today that it has been awarded a $12 million grant by the Bill & Melinda Gates Foundation for the development of a breakthrough vaccine manufacturing platform with the objective of radically lowering...
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.